GLP-1 receptor agonists or DPP-4 inhibitors: how to guide the clinician?

Abstract

Pharmacological treatment of type 2 diabetes has been enriched during recent years, with the launch of incretin therapies targeting glucagon-like peptide-1 (GLP-1). Such medications comprise either GLP-1 receptor agonists, with short (one or two daily injections: exenatide, liraglutide, lixisenatide) or long duration (one injection once weekly: extended-released exenatide, albiglutide, dulaglutide, taspoglutide); or oral compounds inhibiting dipeptidyl peptidase-4 (DPP-4), the enzyme that inactives GLP-1, also called gliptins (sitagliptin, vildagliptin, saxagliptin, linagliptin, alogliptin). Although both pharmacological approaches target GLP-1, important differences exist concerning the mode of administration (subcutaneous injection versus oral ingestion), the efficacy (better with GLP-1 agonists), the effects on body weight and systolic blood pressure (diminution with agonists versus neutrality with gliptins), the tolerance profile (nausea and possibly vomiting with agonists) and the cost (higher with GLP-1 receptor agonists). Both agents may exert favourable cardiovascular effects. Gliptins may represent a valuable alternative to a sulfonylurea or a glitazone after failure of monotherapy with metformin while GLP-1 receptor agonists may be considered as a good alternative to insulin (especially in obese patients) after failure of a dual oral therapy. However, this scheme is probably too restrictive and modalities of using incretins are numerous, in almost all stages of type 2 diabetes. Physicians may guide the pharmacological choice based on clinical characteristics, therapeutic goals and patient's preference.

• Authors: André J Scheen
• Journal: Annales d'endocrinologie (Ann Endocrinol (Paris)) Vol. 74 Issue 5-6 Pg. 515-22 (Dec 2013) ISSN: 2213-3941 [Electronic] France
• PMID: 23570814 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2013. Published by Elsevier Masson SAS.

Chemical References

• Dipeptidyl-Peptidase IV Inhibitors
• GLP1R protein, human
• Glucagon-Like Peptide-1 Receptor
• Hypoglycemic Agents
• Receptors, Glucagon

Topics

• Choice Behavior
• Diabetes Mellitus, Type 2 (drug therapy)
• Dipeptidyl-Peptidase IV Inhibitors (therapeutic use)
• Glucagon-Like Peptide-1 Receptor
• Humans
• Hypoglycemic Agents (therapeutic use)
• Practice Guidelines as Topic
• Receptors, Glucagon (agonists)